Wellington Management Group LLP Reduces Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Wellington Management Group LLP lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 90.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,135 shares of the company's stock after selling 376,120 shares during the period. Wellington Management Group LLP owned about 0.13% of Medpace worth $13,002,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. R Squared Ltd bought a new position in shares of Medpace in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. bought a new position in Medpace in the fourth quarter valued at about $31,000. Jones Financial Companies Lllp boosted its stake in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of research reports. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and cut their target price for the stock from $370.00 to $328.00 in a report on Monday. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, Mizuho reduced their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Ten analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $357.50.

Medpace Trading Up 0.2 %

Shares of NASDAQ MEDP traded up $0.49 during mid-day trading on Tuesday, hitting $305.77. The company had a trading volume of 148,721 shares, compared to its average volume of 319,908. The stock's 50-day moving average price is $322.58 and its 200-day moving average price is $334.29. The company has a market capitalization of $9.24 billion, a price-to-earnings ratio of 24.19, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 1 year low of $272.00 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.